We are planning an innovative and exciting educational experience at SIOP 2021.

Click on the button below to review the detailed interactive programme.
Review the confirmed sessions and speakers, and stay tuned for additional updates!

Detailed Programme

The Congress programme will be running on  Eastern Daylight Time (EDT, UTC-4)
If you cannot join a session live, you can watch its recording afterwards.

SIOP 2021 Programme Highlights:

Lillian Sung, SIOP Scientific Committee Chair, introduces the 2021 Programme and highlights you can look forward to:

Discover more session highlights from the list below or check out the interactive programme for the full overview.

Germ Cell Tumours: What we have learned from MaGIC and how this model of collaboration can apply to other cancers

James Nicholson, UK

Increasing Enrollment of Adolescents and Young Adults with Cancer in Clinical Trials

David Freyer, USA

Identifying cells of origin

Sam Behjati, UK

Brain tumors in infants

Stefan Rutkowski, Germany

Biomarker development  including circulating tumor cells and cell free DNA

Brian Crompton, USA

D’angio lecture -Genomic guided radiotherapy for children : a new Era?

Anita Mahajan,USA

Endocrine Tumors (IPSO)

Paul Losty, UK

Therapeutic opportunities for cancer predisposition syndromes

David Malkin, Canada

The imperative to listen to the child’s voice in pediatric oncology

 Ulrika Kreicbergs, Sweden

1. Addressing mental health across the cancer trajectory

Convener: Gisela Michel, Switzerland

Screening for mental health problems in childhood cancer survivorship

Gisela Michel, Switzerland

Mental health care needs in childhood cancer patients and survivors

Jordan Gilleland Marchak, USA

Mental health of childhood cancer patients and survivors during the COVID-19 pandemic

Fiona Schulte, Canada


2. Generating intelligence from data with advanced analytics including machine learning

Convener: Lillian Sung, Canada

Introduction to Machine Learning – What it is and What it Isn’t?

Lillian Sung, Canada

Application of Machine Learning in the Hospital Setting

David Scheinker, USA

Application of Machine Learning in Public Health and Health Systems

Laura Rosella, Canada


3. Immunotherapies for solid tumors

Convener: Claudia Rossig, Germany

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma

Lenid Metelitsa, USA

Strategies for overcoming escape from CAR T cell targeting in pediatric solid cancers

Claudia Rossig, Germany

Combining antitumor antibodies with CD47 „don´t eat me“ blockade for immunotherapy of neuroblastoma and childhood sarcomas

Robbie Majzner, USA


4. Major Issues in Peadiatric Cancer Survivorship

Convener:  Melissa Hudson, USA

Evolving patterns of cancer treatment-related morbidity

Melissa Hudson, USA

Progress in characterizing reproductive health risks and fertility preservation

Treatment and genetic factors underlying risks for subsequent malignant neoplasm

Lucie Turcotte, USA


5. PROS Symposium : Management of Craniopharyngioma

Radiotherapy Management of Craniopharyngioma

Beate Timmerman, Germany

Surgical Management

Robert Buckley, USA

Medical management , pediatrician point of view

Gesina Keating, USA


6. Implementation and results of SIOP PODC adapted treatment guidelines in low income countries

Convener: Trijn Israels, The Netherlands

Global implementation and results of SIOP PODC Adapted Treatment Guidelines

Ramandeep Arora, India

The Collaborative Wilms Tumour Africa Project – use and results of a SIOP PODC adapted treatment guideline

Vivian Paintsil, Ghana 

Adapted treatment guidelines in sub-Saharan Africa – lessons learned and the way forward

Trijn Israels, The Netherlands


7. SIOP/PROS/IPSO symposium-Multidisciplinary management of pelvic tumors

Convener: Andrea Hayes-Jordan, USA

Surgical approach for pelvic sarcomas, what´s new?

Andrea Hayes-Jordan, USA

Rrhabdo and Non-Rhabdo Pelvic Sarcoma: point of view of the radiation oncologist

Normand Laperriere, Canada

The management of bladder/prostate, vaginal and “other” rhabdomyosarcomas of the pelvis

Rajkumar Venkatramani, USA


8. Tyrosine Kinase Inhibitor Therapy: Beyond ABL Inhibition

Convener: Andrea Biondi, Italy

Ph+ ALL: Current International Clinical Trial and Future Directions

Andrea Biondi, Italy

Ph+ALL: Two Decades Experiences with Tyrosine Kinase Inhibitor

Lewis Silverman, USA

CML: What Do We Want to Know?

Kirk Schultz, Canada


9. St. Baldrick’s Lecture:Biological insights and how they inform targeted therapies in Hodgkin lymphoma

Convener: Monica Metzger, USA

Biological targets and biomarkers in Hodgkin lymphoma

Christian Steidl, Canada

Imaging and biologic biomarkers to guide tailored therapy in pediatric Hodgkin lymphoma

Christine Mauz-Körholz, Germany

Translation of targeted therapy into pediatric frontline clinical trials for Hodgkin lymphoma

Monica Metzger, USA

Choosing the ideal immunotherapy in ALL

Convenor: Andre Baruchel, France

Best treatment for relapsed ALL : the place of bispecific and HSCT

Patrick Brown, USA

Best treatment for relapsed ALL : the place of CAR-T cells

Rebecca Gardner, USA

The ideal immunotherapy of ALL : a tentative synthesis

Andre Baruchel, France


Is there still a role for stem cell transplantation in neuroblastoma

Convenor: Jaume Mora, Spain

Is there still a role for stem cell transplantation in neuroblastoma? YES

Is there still a role for stem cell transplantation in neuroblastoma? NO

Shakeel Modak, USA

Perspective and Consequences Worldwide

Jaume Mora, Spain

Current knowledge in Osteosarcoma

Richard Gorlick, USA

The emerging role of  child centered care – should it replace family  centered care?

Inger Kristensson Hallström, Sweden

Everything you wanted to know about advanced molecular classification in pediatric brain tumors

Michael Taylor, Canada